FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for relapsed or refractory mantle cell ...
© Medical News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.